CONCLUSION: While neurofeedback shows promise in reducing ADHD symptoms, its long-term efficacy and comparability to pharmacological treatments remain inconclusive. Future large-scale, well-controlled trials are needed to establish robust, standardized protocols. Integrating NFB within a personalized, multimodal treatment framework may enhance clinical outcomes, particularly when tailored to EEG-based ADHD subtypes.
